Dewpoint Therapeutics nominated a first‑in‑class small‑molecule development candidate designed to modulate aberrant MYC‑driven transcription by targeting biomolecular condensates that organize oncogenic control. The nomination follows increased interest in condensate biology as a therapeutic axis for transcription‑driven cancers. Complementing this, researchers published a rapid discovery method for identifying cellular biomolecular condensates and their protein components, accelerating target identification and functional studies. The methodological advance promises higher throughput mapping of phase‑separated structures, which are often implicated in transcriptional regulation and disease. Together these moves show both translational and basic‑science momentum: companies are pushing condensate modulators toward the clinic while new discovery tools expand the targetable condensate landscape.